儿童自身免疫性肝炎临床特点及疗效分析

摘要/Abstract

摘要： 目的探讨自身免疫性肝炎(AIH)患儿的临床特点及疗效。方法选取2014年6月至2019年6月西宁市中医院收治的AIH患儿22例。泼尼松2 mg/(kg·d)(最大剂量60 mg/d)治疗1个月后予硫唑嘌呤2 mg(kg·d)(最大100 mg/d), 治疗3个月后逐步减少激素药物剂量直至停止。组间比较采用t检验、Kruskal-Wallis H检验和卡方检验。结果 22例AIH患儿中表现为6例急性病程, 10例亚急性病程, 6例慢性病程。13例为AIH I型, 5例为AIH II型, 4例为未分型, 三组分型患儿一般资料之间均差异无统计学意义(P>0.05)。AIH I型患者GLO为(35.2±9.8)g/L显著高于AIH II型患儿的(24.1±6.7)g/L;AIH I型患儿IgG为(27.4±5.2)g/L高于AIH II型患儿的(19.7±4.4)g/L, 差异有统计学意义(P<0.05);两种分型患儿ALT、AST及TBil均差异无统计学意义(P>0.05)。患儿肝脏组织学中界面性肝炎12例, 浆细胞或淋巴细胞浸润18例, 肝纤维化22例, 玫瑰花结6例, 胆管病变3例, AIH I型、AIH II型及未分型患儿肝脏组织学差异无统计学意义(P>0.05)。治疗有效21例, 难治6例, 复发11例, AIH I型、AIH II型及未分型患者治疗有效、难治及复发例数差异无统计学意义(P>0.05)。结论 AIH I型、II型及未分型患儿临床表现多样, 实验室指标、肝脏组织学结果较为严重, 泼尼松+硫唑嘌呤可以有效改善病情, 但治疗后易复发, 需坚持治疗。

关键词: 自身免疫性肝炎, 硫唑嘌呤, 免疫球蛋白G, 界面性肝炎

Abstract: Objective Clinical characteristics and therapeutic effect of children with autoimmune hepatitis (AIH).Methods A total of 22 children (6 males and 14 females) with AIH admitted to our department from June 2014 to June 2019 were selected with an average age of (9.5 ±4.4) years. The treatment was prednisone 2 mg/kg/d (maximum dose 60 mg/d) 1 month after azathioprine treatment 2 mg/kg/d (maximum 100 mg/d). After 3 months of treatment, the hormone drug dose was gradually reduced until it stopped. The measurement data were expressed as (±s) or [M (P25, P75)], t-test or Kruskal-Wallis H test; the counting data were expressed as absolute numbers and compared by chi-square test.Results Among the 22 cases of AIH, 6 cases were acute course, 10 cases were subacute course and 6 cases were chronic course. 13 cases were AIH type I, 5 cases were AIH type II, 4 cases were unclassified. There was no significant difference among the three groups (P>0.05). GLO in patients with AIH type I [(35.2±9.8) g] was significantly higher than that in patients with AIH type II [(24.1±6.7) g, P<0.05]. The IgG of patients with AIH type I [(27.4±5.2) g] was significantly higher than that of patients with AIH type II [(19.7±4.4g) g, P<0.05], but there was no significant difference in ALT, AST and TBIL between the two types (P>0.05). The results of liver histology included interfacial hepatitis (n = 12), plasma cell or lymphocyte infiltration (n = 18), hepatic fibrosis (n = 22), rosette (n = 6) and bile duct lesion (n = 3). There was no significant difference in liver histological results among AIH I, AIH II and unclassified patients (P>0.05). All patients were followed up after treatment, 21 cases were effective, 6 cases were refractory and 11 cases were recurrent. there was no significant difference in the number of effective, refractory and recurrent cases between AIH type I, AIH type II and unclassified patients (P>0.05).Conclusion The clinical manifestations of AIH type I, II and unclassified children are various, and the laboratory indexes and liver histological results are more serious. Prednisone + azathioprine can effectively improve the condition of AIH patients, but the patients are prone to recurrence after treatment and need to adhere to the treatment.

Key words: Autoimmune hepatitis, Azathioprine, Immunoglobulin G, Interfacial hepatitis

那熹, 王伟, 何建青. 儿童自身免疫性肝炎临床特点及疗效分析[J]. 肝脏, 2020, 25(6): 588-590.

NA Xi, WANG Wei, HE Jian-qing. Analysis of clinical characteristics and curative effect of autoimmune hepatitis in children[J]. Chinese Hepatolgy, 2020, 25(6): 588-590.

参考文献 15

[1]	Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 12:1-17.
[2]	Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology, 1997, 25:541-547.
[3]	Czaja AJ. Under-evaluated or unassessed pathogenic pathways in autoimmune hepatitis and implications for future management. Dig Dis Sci, 2018, 63:1706-1725.
[4]	Balitzer D, Shafizadeh N, Peters MG, et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol, 2017, 30:773-783.
[5]	Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children-what is different from adulthood? Best Pract Res Clin Gastroenterol, 2011, 25: 783–795.
[6]	Chong VH, Jalihal A, Telisinghe PU. Autoimmune hepatitis in adult and pediatric patients: is there any difference. Indian J Gastroenterol, 2015, 34:264-5.
[7]	Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48: 169-176.
[8]	Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999, 31: 929-938.
[9]	Karim F, Loeffen J, Bramer W, et al. IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatr Rheumatol Online Journal, 2016, 14:18-22.
[10]	Rollins-Raval MA, Felgar RE, Krasinskas AM, et al. Increased numbers of IgG4-positive plasma cells may rarely be seen in lymph nodes of patients without IgG4-related sclerosing disease. Int J Surg Pathol, 2012, 20:47-53.
[11]	Ferri Liu PM, de Miranda DM, Fagundes ED, et al. Autoimmune hepatitis in childhood: the role of genetic and immune factors. World J Gastroenterol, 2013, 19:4455-63.
[12]	Zachou K, Muratori P, Koukoulis GK, et al. Review article: autoimmune hepatitis--current management and challenges. Aliment Pharmacol Ther, 2013, 38:887-913.
[13]	Nares-Cisneros J, Jaramillo-Rodríguez Y. Autoimmune hepatitis in children: progression of 20 cases in northern Mexico. Rev Gastroenterol Mex, 2014, 79:238-43.
[14]	Jiménez-Rivera C, Ling SC, Ahmed N, et al. Incidence and Characteristics of Autoimmune Hepatitis. Pediatrics, 2015, 136:e1237-48.
[15]	Karakoyun M, Ecevit CO, Kilicoglu E, et al. Autoimmune hepatitis and long-term disease course in children in Turkey, a single-center experience. Eur J Gastroenterol Hepatol, 2016, 28:927-30.